Contribution of angiogenic factors in a rat model of pre-eclampsia

American Journal of Nephrology

Volumn 32, Issue 4, 2010, Pages 332-339

  Agunanne, E E ^a   Uddin, M N ^a   Horvat, D ^a   Puschett, J B ^a,b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Angiogenic factors; Hypertension; Marinobufagenin; Proteinuria; Resibufogenin

Indexed keywords

ANGIOGENIC FACTOR; BUFOGENIN; MARINOBUFAGENIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GESTATION PERIOD; HYPERTENSION; LABORATORY TEST; NONHUMAN; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; RAT; URINALYSIS; URINARY EXCRETION;

ANALYSIS OF VARIANCE; ANGIOGENIC PROTEINS; ANIMALS; BLOOD PRESSURE; BUFANOLIDES; CREATININE; FEMALE; GESTATIONAL AGE; HEMATOCRIT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, ANIMAL; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77955620941     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319463     Document Type: Article

References (32)

1. Pridjian G, Puschett JB: Preeclampsia. I. Clinical and pathophysiological considerations. Obstet Gynecol Sur 2002; 57: 598-618.
2. Pridjian G, Puschett JB: Preeclampsia. II. Experimental and genetic considerations. Ob-stet Gynecol Sur 20 02; 57: 619-640.
3. Ness RB, Roberts JM: Heterogeneous causes constituting the single syndrome of pre-eclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996; 175:1365-1370.
4. Roberts JM: Preeclampsia: what we know and what we do not know. Semin Perinatol 2000; 24:24-28.
5. Puschett JB: The role of excessive volume expansion in the pathogenesis of preeclampsia. Med Hypotheses 2006; 67:1125-1132.
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thad-hani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclamp-sia. N Eng J Med 20 04; 350: 672-683.
7. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sell-ke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111 : 649-658.
8. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chai-worapongsa T, Levine RJ, Karumanchi SA: A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gesta-tional age neonates. J Matern Fetal Neonatal Med 2008; 21: 9-23.
9. Wallukat G, Homuth V, Fischer T, Lindschau C , Horst k amp B, Jüpner A, Baur E , Nissen E , Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC: Patients with preeclamp-sia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103:945-952.
10. Ianosi-Irimie M, Vu H V, Whitbred JM, Prid-jian CA, Nadig JD, Williams MY, Wrenn DC, Pridjian G, Puschett JB: A rat model of preeclampsia. J Clin Endocrinol Metab 2008; 93: 285-292.
11. Alper AB, Outland J, Finigan K, Pridjian G, Aina-Mumuney A, Puschett JB: Phenotypic characteristics shared by preeclamptic patients and an animal model of preeclampsia: a pilot study. Am J Hypertens 2006; 19: 947-950.
12. Vu HV, Ianosi-Irimie MR, Pridjian CA, Whitbred JM, Durst JM, Bagrov AY, Fedo-rova OV, Pridjian G, Puschett JB: Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 2005; 25: 520-528.
13. Averina IV, Tapilskaya NI, Reznik VA, Fro-lova EV, Federova OV, Lakatta EG, Bagrov AY: Endogenous Na/K-ATPase inhibitors in patients with preeclampsia. Cell Mol Biol 2006; 52: 19-23.
14. Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA, Bagrov AY: Circulating bufodienolide and cardeno-lide sodium pump inhibitors in preeclampsia. J Hypertens 1999; 17:1179-1187.
15. LaMarca HL, Morris CA, Pettit GR, Nagowa T, Puschett JB: Marinobufagenin impairs first trimester cytotrophoblast differentiation. Placenta 2006; 27:984-988.
16. Uddin MN, Horvat D, Glaser SS, Danchuk S, Mitchell BM, Sullivan DE, Morris CA, Puschett JB: Marinobufagenin inhibits proliferation and migration of cytotrophoblast and CHO cells. Placenta 2008; 29: 266-273.
17. Norwitz ER, Schust DJ, Fisher SJ: Implantation and the survival of early pregnancy. N Eng J Med 2001; 345:1400-1408.
18. Ness RB, Roberts JM: Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996; 175:1365-1370.
19. Uddin MN, Agunanne E, Horvat D, Puschett JB: Alterations in the renin angiotensin system in a rat model of human preeclampsia. Am J Nephrol 2010; 31:171-177.
20. Agunanne E, Horvat D, Uddin MN, Horvat D, Puschett JB: The treatment of preeclampsia in a rat model employing Digibind®. Am J Perinatol 2010; 27: 299-305.
21. Horvat D, Severson J, Uddin M, Mitchell B, Puschett J: Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome. Hypertens Pregnancy 2010; 29: 1-9.
22. Redman CW, Sargent IL: Latest advances in understanding preeclampsia. Science 2005; 308:1592-1594.
23. Solomon CG, Seely EW: Preeclampsia-searching for the cause. N Engl J Med 2004; 350: 641-642.
24. Stepan H, Unversucht A, Wessel N, Faber R: Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49:818-824.
25. Lindheimer MD, Romero R: Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclamp-sia. Hypertension 2007; 50: 35-36.
26. Rana S, Karumanchi SA, Levine RJ, Ven-katesha S, Rauh-Hain JA, Tamez H, Thad-hani R: Sequential changes in antiangiogen-ic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50:137-142.
27. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, Connor JM, Dobbie R: Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, in-trauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007; 109: 1316-1324.
28. Powers RW, Roberts JM, Cooper KM, Gal-laher MJ, Frank MP, Harger GF, Ness RB: Maternal serum soluble fms-like tyrosine ki-nase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop pre-eclampsia. Am J Obstet Gynecol 2005; 193: 185-191.
29. Scott DE: Anemia in pregnancy. Obstet Gyn Ann 1972; 1:219-244.
30. Chesley LC: The renal excretion of sodium in women with preeclampsia. Clin Obstet Gy-necol 1958; 1:317-328.
31. Bernstein IM, Ziegler W, Badger GJ: Plasma volume expansion in early pregnancy. Ob-stet Gynecol 2001; 97:669-672.
32. Uddin MN, McLean LB, Hunter FA, Hor-vat D, Severson J, Tharakan B, Childs EW, Puschett JB: Vascular leak in a rat model of preeclampsia. Am J Nephrol 2009; 30: 26-33.